Introduction {#s1}
============

Pregnancy is a unique immunological challenge in which an antigenically distinct fetus and placenta develop in the uterus of the mother. The complex mechanisms by which the fetus avoids rejection, despite expression of paternal major histocompatibility (MHC) antigens, still remain incompletely understood ([@DMP004C15]). Over 50 years ago, Medawar first proposed the existence of regulatory mechanisms that suppress the maternal immune system ([@DMP004C100]). After discovery of heterogeneity in T helper (Th) cell populations in the 1980s, for several years maternal tolerance towards fetal alloantigens was explored in the context of the Th1/Th2 paradigm, with Th2 cells and cytokines proposed to overrule the Th1 cellular immune response which can lead to fetal abortion ([@DMP004C193]; [@DMP004C121]). However, this explanation is now insufficient and it has become clear that additional regulatory mechanisms involving both the innate and the adaptive compartments of the immune response play important roles ([@DMP004C145]; [@DMP004C182]; [@DMP004C27]; [@DMP004C136]). Understanding the mechanisms responsible for tolerance of the male and female gametes poses a similar challenge, since these also express antigens perceived as foreign by the immune system, but are not rejected.

One emerging focus is the role of specialized populations of T-lymphocytes termed regulatory T-cells. These cells are potent suppressors of inflammatory immune responses, and are essential in preventing destructive immunity in all the tissues of the body. The physiological role of regulatory T-cells is 2-fold. Primarily, they act to control T-cells that react with 'self' antigens but have escaped negative selection from the thymus, and in addition, they limit the extent and duration of responses exerted by T-cells reactive with alloantigens and other exogenous antigens. Thus, regulatory T-cells can be viewed as guardians of tissue integrity, preventing harm that might otherwise be caused by aberrant or uncontrolled immune responses. This homeostatic regulation is pivotal in tissues containing endogenous physiological antigens that escape detection as 'self' due to their tissue-restricted expression, and in epithelial surfaces where tolerance of non-dangerous foreign antigens is essential to normal function. Their unique properties and behaviour, particularly their capacity to suppress responses to tissue-specific antigens and alloantigens, confer the capacity for regulatory T-cells to perform unique functions in the events of reproduction and pregnancy.

This review aims to examine the emerging importance of regulatory T-cells in suppressing immunological attack on the conceptus, spermatozoa and oocytes, and the promise for reproductive medicine of new drugs and technologies for manipulating these cells. The key take-home points relevant to regulatory T-cells in reproductive biology and medicine that emerge from this review are listed in Table [I](#DMP004TB1){ref-type="table"}.

###### 

Key features of regulatory T cells in regulating the immune response to pregnancy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treg cells are potent suppressors of autoimmunity and allograft rejection
  Treg cells are implicated in immune tolerance of the conceptus tissues, oocytes and spermatozoa
  Treg cells are increased in the blood, decidual tissue and lymph nodes draining the uterus in pregnancy
  Deletion of these cells is incompatible with maintenance of allogeneic pregnancy
  Unexplained infertility, miscarriage and pre-eclampsia are linked with numerical and functional Treg deficiency
  Treg cell populations can be expanded *in vitro* or *in vivo* for therapeutic purposes
  Dendritic cells controlling Treg cell populations can be targeted *in vivo* to enhance Treg cell numbers and function
  Development of Treg cell therapies for treating infertility and reproductive pathologies will require knowledge of the antigens, cytokines and hormones regulating these cells
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Methods {#s2}
=======

Initially, we synthesized an overview of the current information on tissue origins and modes of action of regulatory T-cells, drawing mainly on seminal papers at the forefront of this specific field of immunology. We then undertook a systematic review of the published literature on regulatory T-cells in reproductive events spanning gametogenesis to embryo implantation and pregnancy. The papers cited were selected on the basis of relevance and quality from a list generated using combinations of the following search terms in Pubmed: 'regulatory T-cells, Treg cells, Tr1 cells, Th3 cells, ovary, testes, uterus, decidua, placenta, pregnancy, infertility, miscarriage and pre-eclampsia'. Finally, we compiled information drawn from selected key papers on the manipulation and utility of regulatory T-cells for clinical applications in transplantation and autoimmune disease. On the basis of this information, we formulated a perspective on the future prospects for targeting regulatory T-cells in novel therepautic strategies for treatment of infertility and reproductive pathologies.

Regulatory T-cells and immune suppression {#s3}
=========================================

The discovery and classification of regulatory T-cells {#s3a}
------------------------------------------------------

The term 'regulatory T-cells' refers to a family of T-lymphocyte populations with suppressive/regulatory properties that are devoted to maintaining antigen-specific T-cell tolerance. At least three subsets of CD4^+^ regulatory T-cells with distinct suppressive mechanisms are distinguished by their phenotype, cytokine secretion and tissue origin ([@DMP004C78]). These are type 1 regulatory T-cells (Tr1) cells, T-helper 3 (Th3) cells and CD4^+^CD25^+^ regulatory T-cells (Treg cells). Each of these populations has the characteristic capacity to actively inhibit the proliferation and effector function of other T-cells ([@DMP004C49]; [@DMP004C61]; [@DMP004C166]). CD8^+^ T-cells with regulatory properties have also been described, but less is known about their ontogeny, regulation and function ([@DMP004C163]).

The history of regulatory cells/suppressor cells in the immunology literature dates back to the 1970s when T-lymphocytes that were capable of suppressing immune responses were first described and named 'suppressor T-cells' ([@DMP004C54]). However with the lack of a definitive marker, questions regarding their authenticity were raised and attention shifted away from this cell population ([@DMP004C59]), until Treg cells in their existing form were identified as a specialized T-cell subset in 1995 by [@DMP004C139]. Tr1 cells were initially characterized in mouse models of inflammatory bowel disease as potent suppressors of antigen-specific immune responses mediated by interleukin-10 (IL-10) synthesis ([@DMP004C61]). Th3 cells were discovered in mice as mediators of oral tolerance acting to inhibit induction of immunity through secretion of transforming growth factor-β (TGFβ) ([@DMP004C194]). Of the three cell populations, Treg cells have fast become established as perhaps the most potent and widespread suppressive cell lineage in the immune system. Unlike Th3 and Tr1 cells which appear to represent altered differentiation states of conventional CD4^+^CD25^−^ T-cells, Treg cells are believed to comprise a distinct and unique T-cell lineage ([@DMP004C194]). They have now been implicated in critical protective functions in auto-immune disease ([@DMP004C138]), transplantation tolerance ([@DMP004C189]), gastro-intestinal homeostasis ([@DMP004C34]) and inflammatory disease ([@DMP004C188]), and conversely, are a pivotal component of the pathophysiological immune tolerance induced by tumours ([@DMP004C106]). Of the three cell subsets, Treg cells are distinguished by their apparently essential role in reproductive events. Although cells with features reminiscent of Tr1 cells and Th3 cells are present in the uterus ([@DMP004C123]), any role for Tr1 cells appears to be redundant since allogenic pregnancy is not compromised in IL-10 null mutant mice ([@DMP004C195]). The necessity of Th3 cells remains to be tested, but this is more challenging since immunocompetent TGFβ null mutant mice do not survive to reproductive age and suffer non-immune-related reproductive disturbances ([@DMP004C73]). The current review will therefore focus predominantly on the Treg cell subset of regulatory T cells.

Treg cells are a distinct T-lymphocyte subset {#s3b}
---------------------------------------------

Treg cells are defined as a separate cellular subset on the basis of their surface phenotype as well as functional characteristics. Treg cells are one of the four major classes of CD4^+^ T-cells, together with Th1 cells, Th2 cells and Th17 cells ([@DMP004C205]), distinguished from the other classes by their role in tolerance as opposed to immunity (Fig. [1](#DMP004F1){ref-type="fig"}). They comprise 1--3% of CD4^+^ T-cells in humans and 5--10% of CD4^+^ T-cells in rodents ([@DMP004C137]; [@DMP004C157]). Despite the unique suppressive properties of Treg cells compared with other lymphocytes, their cellular features are less distinct. Treg cells are generally identified on the basis of their constitutive expression of surface markers including the interleukin-2 receptor CD25 ([@DMP004C139]), glucocorticoid-induced tumour necrosis factor receptor (GITR) ([@DMP004C99]; [@DMP004C159]) cytotoxic T-lymphocyte associate protein 4 (CTLA-4) ([@DMP004C174]), together with high expression of CD95 and in humans, low expression of CD45RB and CD127 ([@DMP004C2]; [@DMP004C94]) (Table [II](#DMP004TB2){ref-type="table"}). However, each of these markers can also be dynamically expressed on the surface of other cell populations ([@DMP004C40]) and there has been difficulty in identifying a definitive surface marker to distinguish Treg cells from related T-cells.

![The microenvironmental context in which naive CD4^+^ Th0 cells encounter their cognate antigen is a principal determinant of their differentiation fate and development into Treg cells as opposed to Th1, Th2 or Th17 cells.\
Treg cells confer a tolerogenic immune response whereas Th1, Th2 and Th17 cells mediate protective immunity. Signals originating from the DC presenting antigen to the Th0 cell, as well as the relative concentrations of key cytokines in the immediate vicinity, are instrumental. DC, dendritic cell; IL, interleukin; Th1, Th2 and Th17, T-helper type 1, type 2 and interleukin 17-producing Th cell; TGF, transforming growth factor.](dmp00401){#DMP004F1}

###### 

Markers for Treg cells

  Marker    Location         Level of expression by Treg cells   Specificity for Treg cells   Expression by other cell lineages
  --------- ---------------- ----------------------------------- ---------------------------- -----------------------------------
  CD25      Surface          High                                ++                           Effector/memory T cells
  CD95      Surface          High                                ++                           Effector/memory T cells
  GITR      Surface          High                                ++                           Effector/memory T cells
  CTLA-4    Surface          High                                ++                           Effector/memory T cells
  CD45RB    Surface          Low                                 ++                           Effector/memory T cells
  Foxp3     Intra cellular   High                                +++++                        Trophoblast giant cells
  Nrp1      Surface          High                                +++                          Neurons
  LAG-3     Surface          High                                +++                          B cells
  CD127\*   Surface          Low                                 ++++                         Newly activated T cells

\*Humans only.

The search for a specific marker for Treg cells was aided by the identification of a mutation in a gene that resulted in the fatal human autoimmune disease 'immune dysregulation polyendocrinopathy, entropathy, X-linked' (IPEX) and the analogous disease in a spontaneous mutant mouse known as the 'scurfy' mouse. The responsible mutation was located in the gene that encodes a transcription factor of the forkhead/winged-helix family, known as Forkhead Box P3 (*FOXP3* or *scurfin*). Null mutation in this gene leads to a functional defect in the resultant protein and consequently the early onset of a severe lymphoproliferative/auto-immune disease ([@DMP004C23]). The link between *FOXP3* expression and the development and function of the Treg cell was first made by Fontenot *et al*. who noted that *FOXP3* mRNA was elevated in the suppressive CD4^+^CD25^+^ lymphocyte population, and went on to demonstrate that *Foxp3* null mutant mice lacked Treg cells. Subsequently, it was shown that transfer of CD4^+^CD25^+^ lymphocytes rescued *Foxp3* null mutant mice from autoimmune pathologies ([@DMP004C46]). The critical role of Foxp3 protein in the development, function and origins of Treg cells has been further explored in recent publications utilising a *Foxp3*^gfp^ knock-in allele, which validated this gene as the 'master-switch' for Treg development ([@DMP004C47], [@DMP004C48]). Discovery of a definitive marker for Treg cells has allowed investigation of the origin and regulation of these cells, and has facilitated examination of their role in many disease states and physiological conditions.

Ontogeny of Treg cells {#s3c}
----------------------

The precise origins and pathways of generation of Treg cells are active topics of research. It is becoming evident that there is heterogeneity in the ontogeny of Treg cells, with the processes through which Treg cells are generated, and the tissue in which they originate, being important factors in their suppressive function and target antigen repertoire as mature cells. At least two distinct pathways of Treg generation appear to exist. First, 'natural' Treg cells can originate via a selective process in the thymus based on the structure of their individual T-cell receptors (TCRs) ([@DMP004C74]; [@DMP004C47]). However, the thymus is not the sole source of Treg cells and there is now compelling evidence that the majority are 'inducible' Treg cells generated within peripheral tissues, particularly in later life when the thymus undergoes extensive involution (reviewed in [@DMP004C3]). As a result, the gross pool of Treg cells at any one time is the sum of the cells selected for survival in the thymus and those cells generated in the periphery.

Treg cell generation in the thymus {#s3d}
----------------------------------

The fate of T-cells differentiated in the thymus is ultimately determined by the varying avidities for self-antigens of the TCRs expressed on their surface. T-cell survival in the thymus is the result of a sequential selection process based on the interaction between naive T-cells and the thymic stromal epithelium. Depending on the avidity of the interaction between the TCR of an individual T-cell and the MHC/self-antigen peptide complex expressed by stromal cells, neglect, positive selection or negative selection can ensue ([@DMP004C186]). Failure to interact with MHC molecules presenting self-antigen on the thymic epithelial cells leads to apoptosis of the T-cell through the lack of TCR signalling (neglect). Positive selection is the result of a TCR signal of sufficient avidity to signify a T-cell\'s ability to recognize self-MHC complexes, whereas a high avidity TCR/antigen interaction is indicative of excessive reactivity to self and hence a potentially pathological self-reactive T-cell, leading again to apoptosis of the T-cell (negative selection). In summary, 'the thymus selects the useful, neglects the useless and destroys the harmful' ([@DMP004C186]).

The generation of natural Treg cells in the thymus is believed to occur as the result of an altered negative selection process. Commitment of naive T-cells to Treg cell differentiation is thought to result when their TCR/antigen affinity is just weaker that that needed for negative selection, but at the extremity of the spectrum for positive selection ([@DMP004C80]) (Fig. [2](#DMP004F2){ref-type="fig"}). In other words, Treg cells derived from the thymus are selected largely on the basis of their capacity to interact with self-antigens, and this interaction is implicit in their role for protection against pathological self-reactive immune responses. Thymic-generated Treg cells are thus thought to function primarily in protection from a range of autoimmune diseases (reviewed in [@DMP004C138]).

![Treg cells are selected in the thymus when the avidity of their TCR for self-MHC is lower than the threshold for negative selection by apoptosis, but higher than the threshold for positive selection of effector T cells.](dmp00402){#DMP004F2}

Treg cell generation in peripheral tissues {#s3e}
------------------------------------------

Maintenance of Treg cell numbers over the human life span, despite the extensive and early involution of the thymus, indicates an alternate source of Treg cell generation independent of the thymus. Peripherally, there appears to be both *de novo* generation of inducible Treg cells and maintenance and expansion of the existing Treg cell pool ([@DMP004C153]; [@DMP004C35]). The role of peripheral tissues in sustaining Treg cell populations was elegantly demonstrated by the observation that ablation of a tissue depletes the ability of donor Treg cells to prevent organ-specific autoimmune disease after adoptive transfer into intact recipients, compared with Treg cells from unmodified donors ([@DMP004C153]). This shows that the presence of peripheral tissue antigens is essential for the *de novo* generation of antigen-specific regulatory T-cells from naive T-cell precursors ([@DMP004C153]). The importance of tissue-specifc antigens for generation of Treg cells to protect against autoimmunity is also shown in other tissues, including the ovary ([@DMP004C141]) (see later). A similar conclusion is drawn from TCR transgenic mouse models, which show that with persistent low levels of antigenic stimulation, naive cells can be induced to express the hallmark Treg cell marker *Foxp3* and take on a suppressive phenotype ([@DMP004C1]).

A related explanation invokes a role for peripheral tissue antigens in providing a maintenance signal for existing Treg cells through promoting proliferation and survival after TCR engagement. Although it is widely reported that Treg cells are characteristically anergic following TCR stimulation *in vitro*, adoptive transfer experiments show that these cells can proliferate *in vivo* ([@DMP004C52]; [@DMP004C45]; [@DMP004C191]), suggesting their proliferation contributes to maintaining and expanding the *in vivo* Treg pool. Critically, proliferation is dependent on the presence of cognate antigen for the Treg TCR ([@DMP004C191]). The likely reality is that peripheral antigens are critical for both the generation of new Treg cells and the maintenance of pre-existing Treg cells.

Although the role of peripheral tissues in Treg cell generation is established in rodent models, a new understanding of human peripheral Treg cell generation is evolving. Recently, it has emerged that *FOXP3* expression is a constitutive product of human (but not mouse) T-cell activation, although typically expression is transient and rapidly down-regulated ([@DMP004C192]). This has led to speculation that *FOXP3* induction and subsequent suppression might be a default pathway in the activation of all human T-cells ([@DMP004C116]); however, debate continues over the suppressive qualities of transiently FOXP3^+^ T-cells ([@DMP004C5]). Constitutive expression of *FOXP3* during T-cell activation supports the plausibility of peripheral Treg cell generation being the predominant pathway in humans, but raises the question of how and why *FOXP3* expression is extinguished in some cells but not others.

Importantly, the pathway of peripheral Treg cell generation provides a mechanism by which these cells might be generated with affinities for antigens not expressed in the thymus. Instead, peripherally generated Treg cells can express TCRs restricted to specific peripheral tissue antigens. This enables the immune system to regulate responses to exogenous antigens that are foreign to self, but against which aggressive responses are not appropriate, and equips the immune system with plasticity in the Treg cell repertoire facilitating dynamic change and adaptation to the environment. Importantly for reproductive events, this property allows the generation and expansion of Treg cell populations with affinities for reproductive antigens associated with the developing conceptus or expressed by sperm or oocytes, which are absent from the thymus.

Treg cell control by dendritic cells, co-stimulatory signals and indoleamine 2,3-dioxygenase {#s3f}
--------------------------------------------------------------------------------------------

The microenvironmental context in which naive CD4^+^ Th0 cells encounter their cognate antigen is the principal determinant of their differentiation fate and development into Treg cells as opposed to Th1, Th2 or Th17 cells (Fig. [1](#DMP004F1){ref-type="fig"}) ([@DMP004C165]; [@DMP004C131]; [@DMP004C205]). Dendritic cells (DCs) are professional antigen-presenting cells which exhibit considerable heterogeneity in their ontogeny, maturation status and accompanying functional phenotype, reflected in the combination of surface signalling molecules and cytokines they express ([@DMP004C105]). The dialogue between Treg cells and a specific class of DCs termed 'tolerogenic DCs' is pivotal in the activation and expansion of Treg cells ([@DMP004C165]). Initially tolerogenic DCs were defined on the basis of their immature or semi-mature phenotype, altered expression of co-stimulatory molecules CD80 and CD86, and lack of expression of the Th1-inducing cytokine IL-12 ([@DMP004C165]), but even mature DCs can drive Treg cell proliferation when differentiated appropriately ([@DMP004C197]).

Certain co-stimulatory signals on DCs can down-regulate Treg-mediated suppression. Members of the tumour necrosis factor (TNF) receptor superfamily, including GITR, OX40, 4-1BB and RANK are expressed by Treg cells and their ligation can block suppression, increase proliferation, or both ([@DMP004C30]; [@DMP004C83]; [@DMP004C183]).

The cytokine environment is critical in controlling DC phenotype and hence the signals sent to Treg cells. DCs differentiated in the presence of TGFβ, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 possess the immunotypic and functional features of immature DCs and reliably induce CD4^+^CD25^+^ Treg cells with immunosuppressive function ([@DMP004C149]).

Another important characteristic of tolerogenic DCs is expression of indoleamine 2,3-dioxygenase (IDO). In plasmacytoid DCs, IDO expression confers the ability to directly activate resting Tregs for potent suppressor activity, and is implicated in converting CD4^+^CD25^+^Foxp3^+^ Tregs from CD4^+^CD25^−^ T-cells and maintaining Treg suppressive activity both in mice ([@DMP004C156]) and in humans ([@DMP004C29]). This is additional to the ability of IDO-expressing DCs to dominantly inhibit T-cell activation by other non-suppressive DCs ([@DMP004C108]). Bi-directional signalling between Treg cells and tolerogenic DCs may be one means of infectious tolerance, since Treg cells can condition DCs to express IDO and thereby exert a suppressive influence over neighbouring T-cells ([@DMP004C60]; [@DMP004C107]). Induction of IDO may occur via ligation of the costimulatory molecule B7 (CD80/CD86) by CTLA-4, a molecule constitutively expressed on Treg cells, with this pathway ultimately also interfering with DC capacity to activate effector T-cell function ([@DMP004C60]).

Cytokines, prostaglandins and toll-like receptors in Treg cell generation {#s3g}
-------------------------------------------------------------------------

Like all T-cells, Treg cells require ligation of their TCR with cognate antigen and IL-2 in order to differentiate from naive CD4^+^ T-cell precursors. Studies in IL-2-deficient mice show that IL-2 is essential for Treg cell generation, and whereas high concentrations of IL-2 can block suppression, low levels of IL-2 modulate their development and maintenance ([@DMP004C152]). IL-15 can substitute for IL-2 in Treg generation, and potentiates Treg cells for further rounds of IL-15-induced proliferation ([@DMP004C86]).

A crucial question is the nature of the cytokines and environmental signals that cause fate commitment to Treg cells, rather than Th1, Th2 or Th17 phenotypes. One key factor is TGFβ, a cytokine long recognized to have immune suppressive and anti-inflammatory properties ([@DMP004C58]). There is evidence that TGFβ acts to override the default pathway that generates T-cells with no suppressive capabilities ([@DMP004C137]; [@DMP004C157]). Naive CD4^+^CD25^−^ T-cells differentiate into a suppressor T-cell phenotype and express *Foxp3* when TGFβ is present at the time of TCR challenge ([@DMP004C28]). TGFβ is also implicated in proliferation of mature Treg cells through modifying the function and signalling capabilities of DCs ([@DMP004C56]). Prostaglandin E~2~ (PGE~2~) may synergize with TGFβ in this role, since *in vitro* experiments indicate that PGE~2~ can enhance the inhibitory capacity of human CD4^+^CD25^+^ Treg cells and induce a regulator phenotype in CD4^+^CD25^−^ T-cells ([@DMP004C12]).

Additional cytokines, including several prominently expressed in the implantation site and gestational tissues, can modulate Treg cell proliferation and suppressive function (reviewed in [@DMP004C168]; [@DMP004C103]). IL-4 and IL-7 are considered growth and survival factors, respectively ([@DMP004C177]; [@DMP004C63]). IL-1 and IL-6 can release resting Treg cells from their anergic state and potentiate responsiveness to proliferative signals ([@DMP004C88]), whereas IL-12 and IL-6 can reverse the suppressive function of Treg cells and rescue Th1 cells from Treg control ([@DMP004C113]; [@DMP004C85]).

An emerging area of central interest is the relationship between Treg cells and pro-inflammatory IL-17-producing T (Th17) cells which, like Th1 cells, are implicated in many autoimmune and inflammatory diseases ([@DMP004C205]). Treg cells and Th17 cells appear to share a common lineage with their relative abundance influenced dramatically by the cytokine environment in which T-cell priming occurs, particularly the ratio of IL-6 to TGFβ ([@DMP004C14]). In the absence of IL-6, TGFβ1 simultaneously induces synthesis of both Foxp3 and the Th17 cell master switch, retinoic acid-related orphan receptor γt (RORγt). Foxp3 then directly interacts with RORγt to suppress the conversion of naive T-cells to Th17 cells ([@DMP004C72]). However, in the presence of IL-6, *Foxp3* expression is down-regulated, allowing RORγt to induce IL-17 synthesis and the conversion of naive T-cells to Th17 cells. IL-1 can also drive commitment to Th17 as opposed to Treg cells ([@DMP004C200]). Existing Treg cells, in the absence of sufficient TGFβ1, can function as inducers of Th17 cells and themselves convert to Th17 cells ([@DMP004C196]). This mutual antagonism and plasticity between Treg and IL-17 cells illustrates the fine line between a suppressive or pro-inflammatory immune outcome, and the major importance of the cytokine environment not only at the outset but for the duration of the response.

Toll-like receptors (TLRs) are expressed by Treg cells and are emerging as key modulators of Treg cell proliferation and behaviour through conferring the ability to sense pathogens and either strengthen or reverse suppressive activity (reviewed by [@DMP004C168]). Ligation of these by pathogen-associated molecular patterns or other TLR ligands such as heat shock proteins leads to a range of different outcomes. Notably, TLR2 ligands increase Treg cell numbers through potentiating their release to antigen-stimulated activation ([@DMP004C167]). Proliferation of Treg cells exposed to TLR2 ligands is accompanied by loss of suppressive function, but withdrawal of the TLR2 stimulus results in immediate recovery of suppressive ability ([@DMP004C167]). Similarly, ligation of TLR8 abrogates Treg suppression ([@DMP004C114]), but in contrast, TLR5 ligation enhances suppressive capacity ([@DMP004C36]). TLR9 ligands such as CpG oligodeoxynucleotides can promote Treg cell generation through stimulating plasmacytoid DCs to increase expression of costimulatory molecule B7, MHC class II and IDO ([@DMP004C29]).

Mechanisms of immune suppression by Treg cells {#s3h}
----------------------------------------------

The mechanisms by which Treg cells exert their suppressive action are still being defined. Treg cells have an extensive and diverse target cell repertoire, and heterogeneous pathways operate depending on the tissue and the identity of the target cell against which suppression is directed. Initially, suppression of activation and proliferation of CD4^+^ T-cells was thought to comprise the principal function of Treg cells ([@DMP004C175]). However, Treg cells are now known to inhibit proliferation and cytokine production in both CD4^+^ and CD8^+^ T-cells ([@DMP004C115]), to suppress B-cell proliferation and immunoglobulin production ([@DMP004C92]), to inhibit cytotoxic function of natural killer (NK) cells ([@DMP004C55]) and inhibit maturation and function of antigen presenting cells including DCs and macrophages ([@DMP004C24]; [@DMP004C102]; [@DMP004C170]). Thus, Treg cells can target several stages of the adaptive immune response, spanning the events of lymphocyte activation and proliferation, through to effector function.

Like all T-cells, Treg cells require engagement of their TCR with cognate antigen to activate their full effector function ([@DMP004C175]). In this regard, Treg cell suppression is antigen-specific, with both pre-existing and newly generated Treg cells needing to encounter antigen in order to exert their suppressive effects. The presence of IL-2 or IL-4 is also critical for Treg cell activation and facilitates further rounds of antigen-driven Treg cell proliferation ([@DMP004C177]). However, once activated, Treg cells are capable of targeting other cells in the vicinity and exerting suppression in an antigen non-specific manner ([@DMP004C176]; [@DMP004C84]).

A major obstacle hindering the definition of Treg cell suppressive action is their apparent multiple and redundant effector mechanisms ([@DMP004C103]). The general consensus is that unlike other types of regulatory T-cells, Treg cells suppress largely in a contact-dependent manner ([@DMP004C8]). Their *in vivo* and *in vitro* activities may differ, with *in vivo* experiments implicating TGFβ and IL-10 in paracrine actions that augment their contact-dependent mechanism of suppression (reviewed in [@DMP004C187]).

Different suppressive mechanisms most likely operate synergistically. It has recently been shown that Treg cells can act as an IL-2 'sponge', competitively depriving adjacent T-cells of autocrine IL-2, and thus preventing the IL-2-dependent processes of T-cell activation and proliferation ([@DMP004C44]; [@DMP004C152]). Additional suppression is mediated by paracrine cytokine production or by cell-to-cell contact either directly between Treg cells and target/effector cells or via third-party cells such as antigen-presenting cells ([@DMP004C175]; [@DMP004C170]). Contact-mediated suppression results from ligation of a range of Treg surface molecules, namely CTLA-4, membrane-bound TGFβ and lymphocyte-activation gene 3 ([@DMP004C181]; [@DMP004C57]; [@DMP004C174]; [@DMP004C70]).

A unique property of Treg cells is their ability to transfer suppressive capabilities to other cellular subsets in a phenomenon known as bystander suppression ([@DMP004C79]). This can be achieved through Treg cells conferring upon target cells the ability to inhibit downstream steps in the immune cascade. For example, Treg cells can modify the phenotype of DCs to become tolerogenic DCs, or induce T cell production of suppressive cytokines such as IL-10 (Hubert *et al*., 2002). This likely explains the notion of infectious tolerance, a process by which suppression to a third-party antigen can be induced via physical association of that antigen with a previously tolerated antigen (reviewed in [@DMP004C190]). This is illustrated when animals of strain A that are rendered tolerant to grafts from strain B demonstrate prolonged tolerance of subsequent grafts from (B×C) F1 animals, and eventually tolerate grafts from strain C animals ([@DMP004C43]; [@DMP004C190]). Such a process allows for a limited repertoire of antigens to induce a dominant tolerant state to a much larger range of antigens that may subsequently be encountered in the same tissue site. This characteristic feature might be of special relevance in reproductive tissues where a variety of antigens would be encountered in association with gametes and the developing gestational tissues. Mast cells, which are abundant in the uterus, have also been implicated as crucial intermediaries of Treg cell tolerance in allograft tissue, operating through secretion of IL-9 ([@DMP004C95]).

Regulatory T-cells in reproductive processes {#s4}
============================================

The unique immunological challenges of reproduction are comparable with situations where mature peripheral tissues express physiological self-antigens that require tolerance, despite their absence of expression in the thymus. Both sperm and oocytes express a range of antigens such as late ontogeny lactate dehydrogenase c4 and the zona pellucida proteins, respectively, that can induce activity autoimmune orchitis and oophoritis when administered to naive recipients ([@DMP004C51]). Similarly, despite modulated expression of MHC antigens by placental cells ([@DMP004C182]), the maternal system shows evidence of activation against paternal MHC and minor antigens during pregnancy in mice ([@DMP004C171]; [@DMP004C204]) and women ([@DMP004C13]). Peripheral tolerance mechanisms are clearly involved in preventing maternal immune rejection of the fetus in pregnancy ([@DMP004C182]). The qualities and functions of regulatory T-cells make these cells perfectly suited to controlling the immune response to reproductive antigens, and there is now substantial evidence confirming their important roles in regulating tolerance to male and female gametes and to the conceptus.

Treg cells in the testes and ovary {#s4a}
----------------------------------

The ovary has been informative in understanding the roles of Treg cells in protecting tissues expressing reproductive antigens from autoimmune destruction. In mice, removal of the thymus shortly after birth causes spontaneous ovarian autoimmune disease, but this can be prevented by passive transfer of T-lymphocytes from spleens of normal adult mice ([@DMP004C141]). The protection-conferring population is now known to be CD4^+^CD25^+^Foxp3^+^ Treg cells, and importantly, cells from females are intrinsically more potent suppressors than cells from males, particularly when retrieved from the lymph nodes draining the ovary ([@DMP004C140]). The gender-specific effect can be reversed if males are grafted with ovaries prior to recovery and transfer of Treg cells ([@DMP004C141]), showing the antigen-specific nature of the Treg suppressive activity and the necessity for persistent presence of the cognate tissue antigen in generating the ovary antigen-specific Treg cells. Autoimmune ovarian disease is believed to result from operational failure of the normal immune regulatory mechanisms required for normal tissue homeostasis ([@DMP004C4]).

The converse situation occurs with male reproductive antigens, where spleen cells from normal male donors are more effective in suppressing epididymitis and orchitis than the Treg cells from female or neonatally orchidectomized donors ([@DMP004C173]), indicating that native testicular tissue is required to generate suppressive cells specifically targeted to antigens in that tissue. The testes appear to have particular physical properties that confer a bias towards generation of Treg cells rather than memory T-cells compared with other sites such as the kidney capsule ([@DMP004C110]), an observation that at least partly explains the long-recognized concept of testicular immune privilege. Interestingly, Sertoli cells may be instrumental in activating testicular Treg cell responses due to their expression of the immune-regulatory co-stimulatory molecule programmed death ligand 1 (PDL1, also known as CD274 or B7-H1) which binds programmed death 1 (PD1) expressed by Treg cells and inhibits proliferation of CD8^+^ T-cells ([@DMP004C38]).

Treg cells in rodent models of pregnancy {#s4b}
----------------------------------------

The first report implicating Treg cells in pregnancy appeared in 2004, when it was shown that CD4^+^CD25^+^ cells increase in number in the blood and lymph nodes of pregnant mice ([@DMP004C7]). An expanded Treg cell pool is detectable in lymph nodes draining the uterus from as early as 2 days after mating, whereas elevated blood levels do not become evident until after implantation ([@DMP004C7]). The increase in Treg cells is associated with accumulation of Foxp3^+^ cells and *Foxp3* mRNA expression in the uterus, as well as elevated lymphocyte suppressive function in the spleen and lymph nodes. The systemic expansion in Treg cell populations occurs independently of fetal alloantigens, since Treg cell numbers are elevated over non-pregnant levels in both syngeneic and allogeneic pregnancies, suggesting involvement of factors such as pregnancy hormones ([@DMP004C7]). However, conceptus alloantigen leads to a greater increase in Treg cell numbers, and is associated with specific suppression of anti-paternal alloantigen reactivity ([@DMP004C203]). The early increase in Treg cell numbers even prior to embryo implantation was confirmed in another study ([@DMP004C178]). Interestingly, the increase in Treg cells is not sustained throughout pregnancy but progressively declines from mid-gestation to return to non-pregnant levels by fetal delivery at term ([@DMP004C203]). CD8^+^ regulatory cells have also been implicated in suppression of fetal immune rejection from early pregnancy in mice ([@DMP004C31]; [@DMP004C16]).

The physiological necessity of Treg cells for pregnancy was elegantly demonstrated using an adoptive transfer model, wherein complete T-cell populations or populations depleted of CD4^+^CD25^+^ Treg cells were transferred into pregnant T-cell-deficient mice ([@DMP004C7]). In the absence of Treg cells, allogeneic fetuses were uniformly rejected, whereas syngeneic fetuses were unaffected ([@DMP004C7]). These findings were confirmed in another approach using passive transfer of CD25-reactive PC61 monoclonal antibody to deplete CD25^+^ cells *in vivo* ([@DMP004C42]). When mice mated with allogeneic or syngeneic males were administered PC61 on the day of mating, activated CD8^+^ and CD4^+^ cell populations were expanded in the lymph nodes draining the uterus and fewer allogeneic fetuses survived to term, whereas no effect on syngeneic pregnancies was observed ([@DMP004C42]). Collectively, these studies support the notion that Treg cells are required to suppress maternal immune responses targeted against fetal alloantigens, rather than male-specific or trophoblast-specific minor histocompatibility antigens.

In a further demonstration of the importance of Treg cells for maternal--fetal tolerance, fewer CD4^+^CD25^+^ cells associated with elevated Th1 cell activity were found in the decidual tissues of abortion-prone CBA/J mice mated with DBA/2J males. Adoptive transfer of Treg cells, purified from normal pregnant mice, elevated decidual *Foxp3* mRNA levels and prevented fetal loss ([@DMP004C201]). Interestingly, transfer of Treg cells from non-pregnant normal mice to the abortion prone mice was ineffective, and transfer of Treg cells on or after day 4 of pregnancy did not prevent abortion ([@DMP004C201]). Consistent with this, depletion of Treg cells using PC61 during the first 2 days of pregnancy led to implantation failure ([@DMP004C201]). Together, these findings show that Treg cells are essential during the first days of pregnancy, even prior to the time of embryo implantation.

Transfer of exogenous Treg to abortion-prone mice was associated with elevated expression of leukaemia inhibitory factor, TGFβ and heme oxygenase-1 at the maternal--fetal interface, whereas IDO as well as Th1 cytokines interferon-γ (IFNγ) and TNFα were unchanged ([@DMP004C202]). These data suggest molecular mechanisms of Treg cell operation are not necessarily restricted to limiting Th1 cells or pro-inflammatory cytokine expression. An interaction between PDL1-expressing decidual cells and PD1 on Treg cells is also essential for Treg-mediated protection of alloantigenic fetuses, since adoptive transfer of Treg cells from wild-type mice reversed the high incidence of alloantigen-expressing fetal death in PDL1 null mutant mice ([@DMP004C62]).

Treg cells in human pregnancy {#s4c}
-----------------------------

Several studies have examined the dynamics of lymphocyte subpopulations during pregnancy in women. An increased expression of CD25 on decidual lymphocytes compared with peripheral blood lymphocytes was described in 1992 ([@DMP004C134]). Later, decreased CD25 expression in decidual tissue of normal pregnancies compared with luteal phase tissue was reported ([@DMP004C26]). However, these studies examined CD25^+^ cells, without regard to markers definitively identifying Treg cells.

The first observations on CD4^+^CD25^+^ cells in human pregnancy described an increase in this subset in early pregnancy decidual tissue ([@DMP004C146]). Other reports demonstrated an increase in circulating CD4^+^CD25^+^ cells during early pregnancy with a peak phase at the second trimester and a decline post-partum to levels slightly higher than pre-pregnancy levels ([@DMP004C65]; [@DMP004C164]). The elevation during the first and second trimesters has been confirmed in studies more precisely identifying Treg cells as CD25^high^ cells ([@DMP004C147]; [@DMP004C135]; [@DMP004C179]; [@DMP004C203]), and a clear decline in CD4^+^CD25^high^ Treg cells occurs during the weeks just prior to delivery ([@DMP004C203]). The CD4^+^CD25^+^ T-cells comprising the expanded pool in pregnancy are highly enriched for FOXP3 and exert suppressive function *in vitro* ([@DMP004C164]). Furthermore, cells expressing the Treg cell activation marker CTLA-4 are more prevalent in peripheral blood and term deciduas of normal healthy pregnant women compared with non-pregnant women ([@DMP004C65]). Several studies report that Treg cells accumulate in decidual tissue at densities greater than in peripheral blood ([@DMP004C147]; [@DMP004C179]). Treg cells from peripheral blood of pregnant and non-pregnant women suppress anti-alloantigen responses *in vitro*, with differential capacity to suppress anti-paternal as opposed to irrelevant alloantigen responses ([@DMP004C104]).

As in mice, Treg cell numbers in women decline as term approaches. The percentage of CD3^+^ lymphocytes that express CD4 and CD25 are significantly decreased in deciduas in spontaneous vaginal delivery compared with elective Caesarean section ([@DMP004C160]). These findings were recently confirmed by a study showing a sharp decrease in CD4^+^CD25^high^ Treg cells towards the end of pregnancy and an increase in CD4^+^CD25^low^ T-cells ([@DMP004C203]). This implies a potential role for Treg cells in the immunological changes preceding labour, and prompts speculation that their decline might be a causal factor in fetal expulsion from the maternal tissues. However, studies using more specific markers and animal models are needed to address the possibility of any active role of Treg cells in parturition.

Treg cells in infertility, miscarriage and pregnancy complications {#s4d}
------------------------------------------------------------------

Several studies report an association between Treg cell paucity and complications of pregnancy (Fig. [3](#DMP004F3){ref-type="fig"}), particularly pre-eclampsia. There is abundant evidence that immunological factors are crucial for the development of this common disease, which in developed countries is responsible for ∼15--20% of maternal mortality ([@DMP004C144]). In pre-eclampsia, Th1 dominance develops together with an increased inflammatory response towards the fetus ([@DMP004C133]; [@DMP004C144]), raising the question of whether this might be secondary to impaired function or decreased numbers of Treg cells.

![Deficiency in Treg cell numbers and/or suppressive function are associated with infertility, recurrent spontaneous abortion and pre-eclampsia in women.\
Studies in mouse models show that in normal pregnancy, adequate Treg cell function acts to suppress Th1-mediated maternal attack of the semi-allogeneic conceptus, but Treg cell depletion leads to insufficient suppression and Th1-mediated fetal loss.](dmp00403){#DMP004F3}

Initially, it was reported that the number of CD3^+^CD25^+^ lymphocytes is decreased in peripheral blood of women with gestational-induced hypertension and especially in the event of pre-eclampsia ([@DMP004C96]); however, no Treg cell specific markers were used to confirm this. Although another study found no association between pre-eclampsia and changes in peripheral blood Treg cell levels ([@DMP004C112]), several subsequent studies have reported that CD4^+^CD25^high^ T-cells are significantly reduced in both the peripheral blood and decidual tissue of pre-eclamptic patients compared with normal pregnant women ([@DMP004C41]; [@DMP004C148]). Observations that the tryptophan catabolizing enzyme IDO is decreased in pregnancies complicated by pre-eclampsia is consistent with diminished Treg cell activity in pregnancy ([@DMP004C143]; [@DMP004C111]), with decreased IDO potentially caused by, and contributing to, insufficient Treg cell activity ([@DMP004C60]). A preliminary report suggests a possible bias towards Th17 cells over Treg cells in women suffering third trimester pre-eclampsia ([@DMP004C142]).

Recurrent spontaneous miscarriage has also been associated with a mal-adaptation in the maternal immune system ([@DMP004C90]). Several studies report increased numbers of CD3^+^CD25^+^ cells in the decidua at the time of spontaneous abortion compared with decidua recovered at therapeutic abortion ([@DMP004C184]; [@DMP004C120]). However, the proportion of Treg cells among these cells is evidently reduced, since both decidual and peripheral blood CD4^+^CD25^high^ T-cells are lower in tissues recovered after spontaneous abortion compared with induced abortions and non-pregnant women ([@DMP004C147]; [@DMP004C199]). Reduced responsiveness to pregnancy-associated expansion of Treg cell populations, due to numerically fewer Treg cells as well as Treg functional deficiency, may underpin a reduced immunosuppressive capability and cause predisposition to miscarriage. In a comprehensive study, women experiencing repeated miscarriage were shown to have a reduced frequency of Treg cells within the peripheral blood CD4^+^ pool, and reduced suppressive capacity, compared with normal fertile women ([@DMP004C10]).

Primary unexplained infertility has also been associated with reduced expression of *FOXP3* mRNA in endometrial tissue ([@DMP004C76]), suggesting that impaired recruitment of Treg cells, or insufficient differentiation of uterine T-cells into Treg cells even prior to conception may affect the capacity to establish pregnancy in women.

Origin and antigen specificity of Treg cells in pregnancy {#s4e}
---------------------------------------------------------

Defining the pathways of Treg generation and the consequences for specific functional roles is critical for understanding how Treg cells operate in reproductive processes, and for designing possible interventions to exploit these cells to improve fertility and pregnancy outcomes. We have only incomplete knowledge of the tissue origins of decidual Treg cells and the roles of conceptus antigens and other factors including cytokines and hormones in driving their expansion in early pregnancy, but there is sufficient emerging information to build a working model (Fig. [4](#DMP004F4){ref-type="fig"}).

![A working model of the key steps in the induction and effector pathways of Treg cell activation, expansion and suppressive function to mediate maternal--fetal tolerance.\
The sequence of events includes (1) antigen uptake and processing within tolerogenic DCs; (2) trafficking of DCs to draining lymph nodes and presentation of antigen fragments on the surface of the DC in association with MHC molecules; (3) interaction between the DC and Treg cells expressing cognate TCRs in the presence of IL-2 and/or IL-15 to elicit their activation and proliferation; (4) recruitment of Treg cell populations from the maternal circulation into the decidual tissue mediated by CCL4 and (5) exertion of specific effector functions, including secretion of IL-10 and TGFβ, and inducing IDO expression in target DCs to further activate and maintain suppressive function in Treg cells, inhibit Th1 cell proliferation and induce Th1 cell apoptosis. Specific cytokines including TGFβ, GM-CSF, IL-4, IL-10, G-CSF and prostaglandin E known to predominate the uterine cytokine milieu are identified as regulators of tolerogenic DCs. Ag, antigen; CCL4, chemokine (C--C motif) ligand 4; DC, dendritic cell; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; MHC, major histocompatibility complex; TGF, transforming growth factor.](dmp00404){#DMP004F4}

In both mice and women, there is evidence of ovarian hormone-regulated fluctuations in uterine Treg cell populations. In mice, administration of 17-β-estradiol (E2) to ovariectomized mice causes elevation in Treg cell numbers and *Foxp3* mRNA expression, and *in vitro* experiments using CD4^+^CD25^−^ cells show direct induction of *Foxp3* by E2 ([@DMP004C117]). Treg cells accumulate in the uterus during the estrus phase of the reproductive cycle as evidenced by elevated *Foxp3* mRNA expression, potentially in response to estrogen-induced expression of several chemokines that target the CCR5 chemokine receptor expressed by Treg cells ([@DMP004C81]). In women, a comparable expansion in CD4^+^CD25^+^FOXP3^+^ Treg cells occurs in the peripheral blood during the late follicular phase of the menstrual cycle, when cell abundance tightly correlates with serum E2 levels, and then is followed by a dramatic decline at the luteal phase ([@DMP004C10]). Direct actions of E2 on Treg proliferation and suppressive function may contribute to these cycle-related fluctuations ([@DMP004C119]). Thus, each reproductive cycle elicits a relative expansion of Treg cell populations. However, it is important to note that since Treg cells require exposure to antigen to exert their full suppressive function, estrogen alone would be insufficient to activate Treg cells for pregnancy, and instead can be viewed as potentiating Treg cells in preparation for stimulation by pregnancy-associated antigens.

The Treg cell pool is further expanded during early pregnancy in mice and humans and several observations suggest that they have a key protective role when the maternal tissues first come into contact with conceptus antigens associated with invading placental trophoblast cells. Both antigen-associated and antigen-independent mechanisms are likely to contribute to the further expansion in Treg cell populations observed in early pregnancy. The thymus appears not to be the origin of the elevated numbers of Treg cells in pregnancy ([@DMP004C203]), so by default a peripheral tissue pathway of generation must occur, in line with studies implicating the uterus draining lymph nodes as the predominant site of Treg pool expansion ([@DMP004C203]). The relatively elevated numbers of Treg cells in tissues of mice bearing allogeneic pregnancies ([@DMP004C82]; [@DMP004C203]) suggest fetal alloantigens act to drive Treg cell proliferation. Non-MHC antigens and non-classical MHC molecules expressed by placental trophoblast cells are implicated, and indeed a population of CD8^+^ T cells with regulatory properties that is activated in response to co-stimulation by the carcinoembryonic antigen family present on trophoblast cells has been described in women ([@DMP004C154]). Heat shock protein-60 (HSP-60) is another candidate trophoblast protein for T-cell recognition ([@DMP004C66]) and is identified as a target antigen for Treg cells in atherosclerosis ([@DMP004C198]). Since antigen presenting cells expressing human leukocyte antigen-G (HLA-G) preferentially induce suppressive activity in CD4^+^ T-cells ([@DMP004C91]), it is possible that trophoblast cell HLA-G also acts to influence the number of Treg cells in the implantation site. Furthermore, PDL1 is strongly expressed by human placental trophoblast cells and a role in influencing cytokine expression by decidual regulatory T-cells is indicated ([@DMP004C172]).

Antigen-driven proliferation of Treg cells is evident in lymph nodes draining the uterus, and might also occur within the decidual tissue, where abundant populations of mature myeloid DCs capable of presenting trophoblast cell antigens are present ([@DMP004C18]). These DCs express markers indicative of a tolerogenic phenotype ([@DMP004C20]) which is likely to be maintained by the GM-CSF, IL-10 and IL-4-dominated cytokine environment of the decidual tissue ([@DMP004C123]). A notable role for an immunoregulatory glycan binding protein, galectin-1 in inducing tolerogenic DCs and supporting their capacity to generate decidual Tr1 cells is shown by loss of allogeneic pregnancies in mice deficient in galectin-1 ([@DMP004C19]).

The mechanisms for recruitment of Treg cells in the decidual tissue after embryo implantation are likely to be modified compared with the non-pregnant state. Expression of chemokine (C--C motif) receptor 5 (CCR5) may facilitate accumulation and retention of antigen-activated effector Treg cells in the implantation site since Treg cells in the gravid uterus are predominantly CCR5^+^. This marker is associated with a highly suppressive phenotype and may be a marker for those cells that have been activated by paternal alloantigen ([@DMP004C82]). One CCR5 ligand in particular, chemokine (C--C motif) ligand 4 (CCL4), is intensely expressed in the gravid uterus and may mediate the further selective accumulation of these cells in pregnancy ([@DMP004C81]). The Treg cells that accumulate in the decidual tissue in pregnancy show specificity in their suppressive function for fetus alloantigens, indicating there is preferential recruitment from maternal peripheral blood, or possibly local expansion of Treg cells reactive with conceptus tissue ([@DMP004C180]).

Consistent with a possible role for normal embryonic development in regulating Treg numbers, CD25^+^CD3^+^ cells are decreased in the decidual tissues of women with ectopic pregnancies, compared to tissues from women with normal pregnancies, while numbers in the peripheral blood were unchanged ([@DMP004C67]). However, interpretation of this study is limited by lack of utilization of a specific marker for Treg cells. Conversely, Treg cells were more abundant in implantation sites in partial and complete molar pregnancies, where Treg cell numbers positively correlated with CD8^+^ cytotoxic T-cells ([@DMP004C109]). An intact conceptus may therefore not be required for recruitment of Treg cells, but a role for trophoblast antigens or immunoregulatory agents seems likely.

Role of seminal fluid in activating Treg cells for pregnancy {#s4f}
------------------------------------------------------------

Exposure to paternal alloantigen occurs in two waves in the reproductive process---initially during transmission of seminal fluid at coitus ([@DMP004C127]), and secondly when placental trophoblast cells invade maternal tissues after embryo implantation ([@DMP004C122]; [@DMP004C75]). This raises the possibility that male alloantigens present in seminal fluid may contribute to activating and expanding the antigen-specific Treg cell pool prior to conceptus antigen encounter. CD4^+^CD25^+^ Treg cell abundance increases within days after mating in mice ([@DMP004C7]) and there is evidence of antigen specificity in the Treg cell response even before embryo implantation ([@DMP004C82]; [@DMP004C203]). In both mice and women, seminal fluid elicits an inflammation-like response in the female reproductive tract associated with recruitment of DCs into the endometrial and cervical tissues ([@DMP004C126]; [@DMP004C124], [@DMP004C125]; [@DMP004C155]). These DCs are capable of processing male antigens in seminal fluid and activating T-cells in draining lymph nodes ([@DMP004C77]). Recent observations in mice exposed to seminal fluid in the absence of conception support a role for seminal fluid in driving Treg cell activation and proliferation, resulting in which promotes tolerance of paternal alloantigens at the time of embryo implantation ([@DMP004C129]). The high levels of TGFβ and prostaglandin E in seminal fluid ([@DMP004C128]) are likely to be important in skewing the T-cell response towards the Treg cell phenotype.

Such a process would explain epidemiological observations that exposure of the mother to the conceiving partners semen reduces the rate of pre-eclampsia ([@DMP004C97]; [@DMP004C130]). Seminal fluid shares many of the same paternal antigens later expressed by the conceptus; however, the nature of Treg cells would not necessitate that the full repertoire of conceptus antigens should be present at the site of initial Treg cell priming. When applied in the context of pregnancy, the notion of bystander tolerance conferred by Treg cells might explain why repeated exposure of the female reproductive tract to a limited panel of paternal antigens in seminal fluid, or alternatively prolonged exposure to a small number of trophoblast antigens early in pregnancy, may be sufficient to prime the maternal immune system to tolerate a wider repertoire of additional antigens expressed later in gestational tissues.

Therapeutic potential of regulatory T-cells in reproductive medicine {#s5}
====================================================================

The pivotal role of Treg cells in pregnancy and the clear association between their deficiency and pregnancy pathologies raise the enticing prospect of exploiting Treg cells in new therapeutic options for pregnancy complications where insufficient immune tolerance is implicated. Although to date there are no reports of efforts to manipulate Treg cell numbers to assist pregnancy, therapeutic interventions for allograft tolerance and auto-immune disease treatment are under development ([@DMP004C33]; [@DMP004C6]) and these might reasonably be extrapolated as candidate treatments for pregnancy disorders. In particular, the potential exploitation of Treg cells to promote tolerance for alloantigens in tissue transplantation is driving extensive efforts to increase Treg cell numbers and/or their suppressive capacity by a variety of strategies (Fig. [5](#DMP004F5){ref-type="fig"}). Emerging insights on the mechanistic basis of tumour-induced tolerance via Treg cell induction ([@DMP004C106]) and studies in animals showing that *in vivo* depletion of Treg cells can drive regression of syngeneic tumours ([@DMP004C158]) have prompted development of therapies to deplete Treg cells for treatment of cancers where tumour-mediated elevation of Treg cells is evident ([@DMP004C50]). The current state of investigation targeting Treg cells in human diseases is summarized below, highlighting features that might be relevant to applications in the reproductive domain.

![Several strategies for increasing Treg cell activity are in development as novel tissue transplantation therapies or treatments for autoimmune disease, and analogous approaches might have applications in reproductive medicine.\
These include (1) administration of IDO-inducing agents or cytokines (such as G-CSF) to expand the pool of tolerogenic DCs; (2) delivery of tolerogenic DCs after pulsing with specific antigen; (3) delivery of antigen in a form such as apoptotic cellular material known to stimulate Treg proliferation and (4) delivery of antigen-specific Treg cells after recovery and *ex vivo* expansion. DC, dendritic cell.](dmp00405){#DMP004F5}

Harvesting and expanding Treg cell populations in vitro {#s5a}
-------------------------------------------------------

A range of strategies is under investigation to expand Treg cell numbers, in both an antigen-specific and a non-specific manner. Current approaches typically involve cell-based therapies using either adoptive transfer of *ex vivo* manipulated Treg cells or induction of *FOXP3* expression in naive lymphocytes ([@DMP004C185]). However, several hurdles need to be overcome before either of these strategies can be implemented. The attractive approach of increasing Treg cell numbers by recovery and expansion of an individual patient\'s Treg cells *ex vivo* ([@DMP004C98]) is currently limited by the ability to isolate Treg cells from human samples with high purity. The intracellular nature of FOXP3 means it cannot be utilized for cell purification.

Typical isolation protocols use magnetic beads that purify cells based on the expression of surface markers such as CD4, using positive selection for these cell types or elimination of non-CD4^+^ cells, followed by multiple rounds of selection for CD25^+^ cells ([@DMP004C69]; [@DMP004C22]). However, this approach fails to yield sufficient purity as CD25 also isolates activated T-cells and fails to discriminate between the CD25^high^ cell population, which includes the majority of human Treg cells, and CD25^intermediate^ cells that largely comprise non-regulatory T-cells. Consequently, when the isolated cells are expanded *in vitro*, the anergic nature of Treg cells means that any contaminating T-cell subsets expand faster and result in a low percentage of the desired suppressive populations ([@DMP004C11]). Adoptive transfer of preparations that contain activated/reactive T-cells could, in opposition to the desired effect, adversely affect tolerance.

Another protocol for isolating Treg cells uses multiple surface markers in combination including CD4, CD25, CTLA4 and CD127, followed by fluorescent-activated cell sorting ([@DMP004C68]; [@DMP004C64]). Although this technique can produce a highly purified population, the quantity of cells generated is substantially lower than with magnetic bead protocols, and as a result, significant levels of *in vitro* expansion are required. This problem has largely been overcome in the past few years. Although traditional protocols expand cell numbers ∼40-fold ([@DMP004C22]; [@DMP004C25]), some current protocols can routinely yield ∼13 000-fold increase in Treg cell numbers in a period of 3--4 weeks ([@DMP004C68]). Importantly, these expanded Treg cells maintain their suppressive capacity and in some cases show increased suppressive ability ([@DMP004C25]). A better understanding of the requirement of signalling and co-stimulatory factors in Treg cell proliferation and homeostasis will allow more efficient expansion protocols. For example, blockade of phospholipase D signalling using primary alcohols in *ex vivo* cultures selectively expands Treg cells over effector T-cells ([@DMP004C161]). The major limiting factor in implementing *in vitro* cell-based therapies is now the lengthy time and cost of such labour intensive procedures. Additionally, standardized procedures and good manufacturing practice in cell-based therapies are yet to be implemented.

Promoting development of Treg cells in vivo and in vitro {#s5b}
--------------------------------------------------------

Alternative strategies for augmenting Treg cell activity involve the manipulation of naive CD4^+^ T-cells to induce *FOXP3* expression. There is a growing body of evidence that FOXP3^+^ cells can be generated from naive T-cells in the periphery through stimulation with low levels of antigen ([@DMP004C9]) or by delivering antigens in association with DCs ([@DMP004C33]; [@DMP004C87]). The efficacy of this approach both *in vitro* and *in vivo* is improved when DCs are conditioned into a tolerogenic phenotype by addition of exogenous cytokines or by transfection with immunosuppressive cytokine genes ([@DMP004C131]). The challenge of this approach is the necessity for pulsing DCs with the appropriate antigen, to ensure that sufficient T-cells expressing cognate TCRs respond.

Ectopic lenti-viral-induced expression of *FOXP3* is another proposed technique for conversion of naive T-cells into suppressive cells. However, whether *FOXP3* transformed cells represent a true regulatory phenotype is still in question ([@DMP004C53]). Furthermore, the amount of *in vitro* manipulation involved in this approach outweighs that required for purification and expansion of pre-existing Treg cells.

The ability to generate new Treg cells *in vivo* without the need for prior isolation and *in vitro* manipulation would circumvent many of the problems and cost involved in the aforementioned approaches. With the incomplete knowledge of the factors driving the generation and maintenance of Treg cells *in vivo*, the ability to expand these cells within an individual is yet to be exploited to its full potential. Currently, few strategies exist to artificially augment Treg cell numbers without the need for *in vitro* manipulation. One current approach involves the concurrent injection of IL-2 and the anti-IL-2 antibody JES6-1. When administered, these form a complex that has high affinity for IL-2Rα (CD25), which is constitutively expressed at high levels on Treg cells, leading to an ∼4-fold selective expansion of CD4^+^CD25^+^ cells ([@DMP004C21]).

Another alternative for driving endogenous regulatory T-cell production might be administration of granulocyte colony-stimulating factor (G-CSF). This cytokine, which is conventionally utilized in treatment of severe chronic neutropenia or in bone marrow transplant patients, has been shown to be efficacious in Treg cell generation ([@DMP004C132]; [@DMP004C131]). G-CSF treatment is reported to induce development of tolerogenic DCs, which in turn elicit potently suppressive regulatory T-cells reminiscent of Tr1 cells ([@DMP004C132]). However, an important pitfall of this approach is the possibility of phenotype reversion in G-CSF-induced DCs, leading to the opposite effect of inducing immunity.

Exploiting the IDO pathway provides additional novel opportunities for manipulating Treg cells *in vivo*. IDO can now be considered a physiological Treg cell activator, and therapeutic treatments to induce IDO expression or augment IDO enzymatic activity in DCs seem feasible options for inducing Treg cells, analogous to mechanisms utilized by tumour cells ([@DMP004C37]). Over-expressing IDO utilizing adenovirus or transposon-mediated gene therapy in lung tissue has been shown to have potent effects on persistence of allogeneic lung transplants, associated with suppression of allo-reactive T-cells ([@DMP004C169]; [@DMP004C93]). An FDA-approved treatment for the rheumatoid arthritis utilizes CTLA-4-Ig to promote tolerance by targeting the IDO pathway. In several animal models, CTLA-4-Ig treatment has been shown to increase allogeneic graft survival and reduce clonal T-cell expansion linked with elevated IDO expression in DCs ([@DMP004C60]; [@DMP004C101]). Importantly, suppression was abrogated by the IDO inhibiting agent 1-methyl tryptophan, implicating IDO as a critical factor in the treatment effect.

Prospects for utilizing Treg cells in treatments for infertility and subfertility {#s5c}
---------------------------------------------------------------------------------

The efforts to devise Treg therapies for tissue transplantation show exciting promise and the lessons learnt will be valuable for developing analogous therapies for reproductive disorders. It seems reasonable that boosting the number and/or activity of Treg cells reactive with appropriate conceptus antigens should confer stronger immune tolerance in women prone to unexplained infertility, miscarriage or pre-eclampsia due to intrinsic tolerance deficiency. Animal studies that support this concept are beginning to appear in the literature, with recent reports of elevated Treg cells protecting against fetal loss in the abortion-prone CBA/J x DBA/2J mouse model ([@DMP004C201]), and exogenous TGFβ delivered at conception boosting vaginal Treg cell numbers and also reducing fetal loss in the CBA/J x DBA/2J model ([@DMP004C32]). Interestingly, the peri-conceptual timing of these successful interventions suggests that in women, Treg cell boosting might be efficacious if achieved even prior to the index pregnancy.

The first reported clinical study targeting the regulatory T-cell nexus has utilized G-CSF treatments in women experiencing recurrent miscarriage. Administration of Filgrastim (G-CSF) for the first 30 days of pregnancy showed promise in a small pilot study in reducing the incidence of subsequent miscarriage ([@DMP004C150]). As expected, G-CSF treatment appears to be associated with an increase in circulating CD4^+^CD25^+^ Treg cells and DCs ([@DMP004C151]). Despite these encouraging initial results and the established safety of this drug ([@DMP004C39]), it is somewhat concerning that pre-clinical animal studies to investigate the effects of G-CSF therapy on fetal and post-natal parameters have not been reported, particularly in view of mounting evidence for cytokine effects on fetal programming ([@DMP004C162]).

Another strategy worthy of clinical evaluation would involve recovery and *in vitro* priming of DCs with male partner MHC antigen, in an approach analogous to treatments under development for allogeneic graft rejection ([@DMP004C131]), utilizing cytokines to condition DCs into a tolerogenic phenotype prior to transfer ([@DMP004C149]). A simpler possibility might involve transferring male partner-derived MHC^+^ apoptotic cells, which would then be processed by recipient DCs *in vivo* ([@DMP004C105]). The validity of these strategies is supported by an experiment in CBA/J x DBA/2J mice where paternal alloantigen-pulsed DCs elicited a short-lived reduction in abortion rates, although whether the effect was mediated through increased Treg cells was not examined ([@DMP004C17]).

Investigation of IDO-inducing reagents such as CTLA4-Ig that are currently in use as immunosuppressants for other clinical applicants also seems worthwhile in the reproductive setting. The benefit of these agents is their generic, antigen-independent nature; however, there may be pitfalls associated with the lack of specific targeting of tissue-specific Treg cell populations.

However, it is important to caution that any attempts in women to alter Treg cell number or function during or prior to pregnancy must be based in a sound biological rationale, informed by knowledge of the antigens against which pregnancy-associated Tregs are normally targeted, and taking into account the natural ontogeny, timing of activation and regulators governing these cells. Compelling pre-clinical animal data will be essential to provide proof-of-concept and to justify any clinical attempt to boost Treg cells in women. Although there are differences in the detail of the precise mechanisms mediating maternal immune tolerance in rodents and humans, the data available to date support the reasonable likelihood of a comparable role for Treg cells in both species. As well as the abortion-prone mouse model, genetic mouse models that allow fine manipulation of Treg cell numbers, such as the DEREG mouse where low-dose diphtheria toxin can be utilized to selectively and acutely deplete Treg cells ([@DMP004C89]), will be valuable tools for more fully defining Treg cell functions in pregnancy.

The long controversy surrounding the use of paternal allo-immunization as a treatment for miscarriage patients resulted from incomplete understanding of the relevant biological mechanisms and failure to engage the correct path to clinical translation ([@DMP004C118]). It is essential that new and promising reproductive immunology therapies do not suffer the same fate. In view of our emerging knowledge on the mechanisms controlling induction of tolerance versus immunity, it seems likely that administration of paternal antigen without appropriate tolerance-inducing agents might in some women aggravate Th1 or Th17-mediated immunity, rather than induce Treg cells.

Comprehensive clinical trials will be essential to ensure that no adverse effects result from manipulating Treg cells. The risk--benefit analysis of experimental treatments in otherwise healthy, reproductive aged women is ethically challenging compared with patients suffering terminal illness or a debilitating autoimmune condition. Relevant concerns might include inadvertently exacerbating an inappropriate immune response, whereas an overly robust maternal Treg response could cause diminished ability to reject chromosomally abnormal embryos, and/or predispose to aggressive placental invasion of maternal tissues (placenta accreta). Increasing susceptibility to choriocarcinoma, gynaecological or unrelated tumours through artificially expanding Treg cell populations is a further serious risk, needing careful and thorough evaluation. Finally, since reproductive pathologies result from multiple aetiologies, robust and practical diagnostics for defining individual women or couples at risk of Treg cell-deficient pregnancy will need to be developed.

Conclusions and future perspectives {#s6}
===================================

Collectively, the emerging literature provides a compelling case that Treg cells have an important role in successful pregnancy. That several studies show a peak of Treg cells in the first trimester of pregnancy implies a particularly important role for Treg cells in implantation and the initial wave of placental invasion of the maternal tissues during early pregnancy. Insufficient Treg cell numbers and/or function appear to be associated with several complications of pregnancy; however, the underlying mechanisms governing Treg cell numbers and function in the implantation site, and the reasons for their deficiency in some reproductive pathologies, are not clear.

To understand the function and dynamics of Treg cells during pregnancy, more basic research is needed. In particular, the origin and nature of the eliciting antigens and the roles of cytokines, IDO, TLR ligands and other regulatory factors driving activation and expansion of conceptus antigen-reactive Treg cell populations in early pregnancy, as well as the chemokine signals regulating their recruitment and retention in the uterus, have to be defined. The utility of many existing studies is limited by their use of CD25 as a Treg cell marker, underscoring the need for consistent use of Foxp3 and other specific surface markers to definitively identify Treg cells. Defining the nature and significance of Treg cell interactions with other uterine leukocyte populations, notably DCs, NK cells and mast cells, should also be a research priority.

There is no doubt that Treg cells offer an attractive target for treatment of disease and hold great promise for reproductive applications; however, ultimately the science of manipulation of Treg cell numbers is still in its infancy. As our understanding of the origins and factors controlling Treg cells expands, their utility as therapeutic agents will begin to be actualized through clinical trial evaluation. Any treatment will need to meet the requirements of safety, efficacy and ease of administration that govern the development of all pharmaceutical agents. Once this is achieved, and with their distinct importance in reproduction, it is highly likely that they will become a powerful new tool for the treatment of fertility pathologies stemming from disturbances in immune tolerance.
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